Adjuvant endocrine therapy for hormone receptor-positive, HER2-negative breast cancer: risk stratification, treatment intensification, and clinical management

The review summarizes current approaches to adjuvant endocrine therapy for hormone receptor-positive, HER2-negative early breast cancer. It discusses clinicopathological and biological recurrence-risk factors, assessment of endocrine sensitivity, and criteria for treatment intensification. Evidence on extended endocrine therapy, ovarian suppression, aromatase inhibitors, and the addition of CDK4/6 inhibitors is presented. Particular attention is paid to prevention of bone loss, management of adverse events, drug-drug interactions, lifestyle modification, and treatment adherence. Individual treatment selection should account for the expected absolute benefit, toxicity, comorbidities, menopausal status, and patient preferences. Adjuvant endocrine therapy is viewed as a dynamic clinical management process that requires regular assessment of efficacy and safety, prevention of complications, and timely treatment modification.

Authors

Institutions

Publication Details

Journal
Medical alphabet
Published
2026-11-17
DOI
https://doi.org/10.33667/2078-5631-2026-27-22-28
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Adjuvant endocrine therapy for hormone receptor-positive, HER2-negative breast cancer: risk stratification, treatment intensification, and clinical management

В. Н. Дмитриев, Пеганова Екатерина Вячеславовна, Владислав Владимирович Петкау, Гармарник Татьяна Валерьевна et al.
Medical alphabet
Breast Cancer Treatment Studies
article

Adjuvant endocrine therapy for hormone receptor-positive, HER2-negative breast cancer: risk stratification, treatment intensification, and clinical management

В. Н. Дмитриев, Пеганова Екатерина Вячеславовна, Владислав Владимирович Петкау, Гармарник Татьяна Валерьевна, Константин Викторович Меньшиков, Елена Владимировна Артамонова, Ирина Альбертовна Королева, М. В. Шомова, O. A. Maslova, R. P. Litvinov, O. A. Gladkov, Elena N. Vorobeva, Антон Беленков, D. E. Neznamov, O. A. Agrishev
article en

Abstract

The review summarizes current approaches to adjuvant endocrine therapy for hormone receptor-positive, HER2-negative early breast cancer. It discusses clinicopathological and biological recurrence-risk factors, assessment of endocrine sensitivity, and criteria for treatment intensification. Evidence on extended endocrine therapy, ovarian suppression, aromatase inhibitors, and the addition of CDK4/6 inhibitors is presented. Particular attention is paid to prevention of bone loss, management of adverse events, drug-drug interactions, lifestyle modification, and treatment adherence. Individual treatment selection should account for the expected absolute benefit, toxicity, comorbidities, menopausal status, and patient preferences. Adjuvant endocrine therapy is viewed as a dynamic clinical management process that requires regular assessment of efficacy and safety, prevention of complications, and timely treatment modification.

Medical alphabet(27)
Pirogov Russian National Research Medical University (RU), Russian Cancer Research Center NN Blokhin (RU), Nizhny Novgorod Regional Clinical Oncology Center (RU), Samara Medical Institute Reaviz (RU), Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky (RU), Ministry of Health of the Russian Federation (RU), Medical Radiological Research Center (RU), Guz "Tul'skiy Oblastnoy Onkologicheskiy Dispanser (RU), Regional Clinical Research (US), Chelyabinsk Regional Clinical Oncology Center (RU)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon